Ophthotech Shares Disintegrate After Failed Phase 3 Trial Of Fovista

Ophthotech Corp OPTH shares are trading sharply lower by $32.85 at $5.92 in Monday's session. The catalyst for the 85 percent decline is the announcement that the primary endpoint in two Phase 3 trials of Fovista was not met.

That news has prompted three Wall Street firms to downgrade the issue.

The meltdown from pre-market trading continued into the regular session. After a sharply lower open from Friday's close ($38.77) to $6.23 on the open, it managed a brief pop to $6.48 before continuing its move lower.

It has now dipped under $6.00, with the current low standing at $5.85 and is attempting to re-enter the $6 handle.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: TechnicalsIntraday UpdateMoversTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!